[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MXPA04003986A - N-azabicyclo-substituted hetero-bicyclic carboxamides as nachr agonists. - Google Patents

N-azabicyclo-substituted hetero-bicyclic carboxamides as nachr agonists.

Info

Publication number
MXPA04003986A
MXPA04003986A MXPA04003986A MXPA04003986A MXPA04003986A MX PA04003986 A MXPA04003986 A MX PA04003986A MX PA04003986 A MXPA04003986 A MX PA04003986A MX PA04003986 A MXPA04003986 A MX PA04003986A MX PA04003986 A MXPA04003986 A MX PA04003986A
Authority
MX
Mexico
Prior art keywords
azabicyclo
substituted hetero
nachr agonists
bicyclic
carboxamides
Prior art date
Application number
MXPA04003986A
Other languages
Spanish (es)
Inventor
Gregory Wishka Donn
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of MXPA04003986A publication Critical patent/MXPA04003986A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

The invention provides compounds of Formula (I), wherein Azabicyclo is I, II, III, IV, V, or VI; W0 is a bicyclic moiety and is (a), (b) or (c). These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals in which alpha7 is known to be involved.
MXPA04003986A 2001-10-26 2002-10-17 N-azabicyclo-substituted hetero-bicyclic carboxamides as nachr agonists. MXPA04003986A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34443601P 2001-10-26 2001-10-26
US34267401P 2001-12-21 2001-12-21
PCT/US2002/031579 WO2003037896A1 (en) 2001-10-26 2002-10-17 N-azabicyclo-substituted hetero-bicyclic carboxamides as nachr agonists

Publications (1)

Publication Number Publication Date
MXPA04003986A true MXPA04003986A (en) 2004-07-23

Family

ID=26993131

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04003986A MXPA04003986A (en) 2001-10-26 2002-10-17 N-azabicyclo-substituted hetero-bicyclic carboxamides as nachr agonists.

Country Status (6)

Country Link
EP (1) EP1438308A1 (en)
JP (1) JP2005511574A (en)
BR (1) BR0213760A (en)
CA (1) CA2464194A1 (en)
MX (1) MXPA04003986A (en)
WO (1) WO2003037896A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (en) 2001-12-27 2003-07-10 Bayer Ag 2-heteroaryl carboxamides
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
HUP0500610A3 (en) 2002-09-25 2013-12-30 Memory Pharm Corp Indazoles, benzothiazoles, and benzoisothiazoles, pharmaceutical compositions comprises thereof and their uses
TW200418848A (en) 2002-10-24 2004-10-01 Glaxo Group Ltd Compounds
WO2004039366A1 (en) * 2002-11-01 2004-05-13 Pharmacia & Upjohn Company Llc Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy
GB0310867D0 (en) 2003-05-12 2003-06-18 Novartis Ag Organic compounds
DE602004031124D1 (en) 2003-08-13 2011-03-03 Neurosearch As NEW CHINUCLIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USE
SG149830A1 (en) 2003-12-22 2009-02-27 Memory Pharm Corp Indoles, 1h-indazoles, 1,2-benzisoxazoles, and 1,2- benzisothiazoles, and preparation and uses thereof
KR101176670B1 (en) 2004-03-25 2012-08-23 메모리 파마슈티칼스 코포레이션 Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
CA2567977A1 (en) 2004-04-22 2006-01-05 Memory Pharmaceutical Corporation Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof
BRPI0510212A (en) 2004-05-07 2007-10-16 Memory Pharm Corp 1h-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and their preparation and uses
PE20060437A1 (en) 2004-06-18 2006-06-08 Novartis Ag AZA-BICYCLONONE COMPOUNDS AS CHOLINERGIC LINKS OF nAChR
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
RU2418797C2 (en) 2004-12-22 2011-05-20 Мемори Фармасьютиклз Корпорейшн LIGANDS OF NICOTINE RECEPTOR α, THEIR OBTAINING AND APPLICATION
US7307094B2 (en) 2005-02-17 2007-12-11 Amr Technology, Inc. Benzoxazole carboxamides for treating CINV and IBS-D
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
DE102006030479A1 (en) 2006-07-01 2008-03-20 Merck Patent Gmbh indazole
MX2009001494A (en) 2006-08-07 2009-04-23 Albany Molecular Res Inc 2-aminobenzoxazole carboxamides as 5ht3 modulators.
US7553846B2 (en) 2006-08-07 2009-06-30 Albany Molecular Research, Inc. 2-alkylbenzoxazole carboxamides as 5-HT3 modulators
LT2889033T (en) 2008-11-19 2018-07-10 Forum Pharmaceuticals Inc. Treatment of negative symptoms of schizophrenia with (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
CA2799744C (en) 2010-05-17 2020-01-28 Envivo Pharmaceuticals, Inc. A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
EP3666272A1 (en) 2012-05-08 2020-06-17 Forum Pharmaceuticals Inc. Use of encenicline in the treatment of cognitive impairment, alzheimer's disease, memory deficit

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4605652A (en) * 1985-02-04 1986-08-12 A. H. Robins Company, Inc. Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes
HU895334D0 (en) * 1986-07-30 1990-01-28 Sandoz Ag Process for the preparation of nasal pharmaceutical compositions
IE62231B1 (en) * 1987-12-24 1995-01-11 Wyeth John & Brother Ltd Heterocyclic compounds
US4863919A (en) * 1988-02-01 1989-09-05 A. H. Robins Company, Incorporated Method of enhancing memory or correcting memory deficiency with arylamido(and arylthiomido)-azabicycloalkanes
US4920227A (en) * 1988-11-29 1990-04-24 Rorer Pharmaceutical Corp. Benzobicyclic carboxamide 5-HT3 antagonists
US4920219A (en) * 1988-11-29 1990-04-24 Rorer Pharmaceutical Corp. Substituted saturated and unsaturated indole quinoline and benzazepine carboxamides and their use as pharmacological agents
JPH04247081A (en) * 1991-02-01 1992-09-03 Takeda Chem Ind Ltd 5-membered heterocyclic acid amide
GB9304500D0 (en) * 1993-03-05 1993-04-21 Glaxo Spa Heterocyclic compounds
SE9904176D0 (en) * 1999-11-18 1999-11-18 Astra Ab New use
SE0000540D0 (en) * 2000-02-18 2000-02-18 Astrazeneca Ab New compounds

Also Published As

Publication number Publication date
EP1438308A1 (en) 2004-07-21
JP2005511574A (en) 2005-04-28
BR0213760A (en) 2004-10-19
CA2464194A1 (en) 2003-05-08
WO2003037896A1 (en) 2003-05-08

Similar Documents

Publication Publication Date Title
MXPA04003986A (en) N-azabicyclo-substituted hetero-bicyclic carboxamides as nachr agonists.
BG108650A (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
MXPA04008152A (en) Azabicyclic compounds for the treatment of disease.
MXPA04004373A (en) Azabicyclic-phenyl-fused-heterocyclic compounds and their use as alpha7 nachr ligands.
MXPA04004464A (en) Azabicyclic-substituted-heteroaryl compounds for the treatment of disease.
MXPA05010496A (en) Positive allosteric modulators of the nicotinic acetylcholine receptor.
WO2003093250A3 (en) Positive allosteric modulators of the nicotinic acetylcholine receptor
GB0220581D0 (en) Organic Compound
WO2002100858A3 (en) Quinuclidine-substituted heteroaromatic compounds as ligands at nicotinic acetylcholine receptors
EA200301121A1 (en) Tartrales 5,8,14-TRIAZETHETRACYCLO [10.3.1.02,11.04,9] HEXADECA-2 (11), 3,5,7,9-PENTAENA
MXPA03011484A (en) Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease.
CA2499330A1 (en) New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
MY140693A (en) [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
WO2002016357A3 (en) Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
SE0300119D0 (en) Novel compounds
SE0102439D0 (en) New compounds
TW200602338A (en) Selected CGRP antagonists, process for preparing them and their use as pharmaceutical compositions
WO2002016358A3 (en) Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
MX2009006018A (en) Quinuclidinol derivatives as muscarinic receptor antagonists.
WO2002015662A3 (en) Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists
HRP20050641A2 (en) New carboxylic acids and the esters thereof, pharmaceutical compositions containing these compounds and processes for the preparation thereof
MX2007010414A (en) Pyridine-2-carboxamide derivatives as mglur5 antagonists.
WO2002016356A3 (en) Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
TW200606151A (en) Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
WO2002016355A3 (en) Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic) acetylcholine receptor ligands